BY Shanley Chien

Since the discovery of KRAS gene mutations in 1983, researchers have worked to develop new therapies that target this protein when treating cancer. Unfortunately, KRAS mutations have long been considered impossible to treat with drugs, but MD Anderson researchers have made recent breakthroughs in developing targeted therapies with promising results.

Shubham Pant, M.D., associate professor of Investigational Cancer Therapeutics...

Illustration of the KRAS mutation

BY Shanley Chien

Nanomedicine is a quickly emerging area of study that uses nanoparticles for drug delivery, diagnoses and in vivo imaging. While nanomedicine...